|
1
|
Li Q, Guo D, Dong Z, et al: Ondansetron
can enhance cisplatin-induced nephrotoxicity via inhibition of
multiple toxin and extrusion proteins (MATEs). Toxicol Appl
Pharmacol. 273:100–109. 2013.
|
|
2
|
Hardie DG: AMP-activated/SNF1 protein
kinases: conserved guardians of cellular energy. Nat Rev Mol Cell
Biol. 8:774–785. 2007.
|
|
3
|
Do MT, Kim HG, Khanal T, et al: Metformin
inhibits heme oxygenase-1 expression in cancer cells through
inactivation of Raf-ERK-Nrf2 signaling and AMPK-independent
pathways. Toxicol Appl Pharmacol. 271:229–238. 2013.
|
|
4
|
Lettieri Barbato D, Vegliante R, Desideri
E and Ciriolo MR: Managing lipid metabolism in proliferating cells:
New perspective for metformin usage in cancer therapy. Biochim
Biophys Acta. 1845:317–324. 2014.
|
|
5
|
Leverve XM, Guigas B, Detaille D, et al:
Mitochondrial metabolism and type-2 diabetes: a specific target of
metformin. Diabetes Metab. 29:6S88–6S94. 2003.
|
|
6
|
Evans JM, Donnelly LA, Emslie-Smith AM,
Alessi DR and Morris AD: Metformin and reduced risk of cancer in
diabetic patients. BMJ. 330:1304–1305. 2005.
|
|
7
|
Anastasiou D: Metformin: a case of divide
and conquer. Breast Cancer Res. 15:3062013.
|
|
8
|
Isakovic A, Harhaji L, Stevanovic D, et
al: Dual antiglioma action of metformin: cell cycle arrest and
mitochondria-dependent apoptosis. Cell Mol Life Sci. 64:1290–1302.
2007.
|
|
9
|
Kemp BE, Stapleton D, Campbell DJ, et al:
AMP-activated protein kinase, super metabolic regulator. Biochem
Soc Trans. 31:162–168. 2003.
|
|
10
|
Sanders MJ, Grondin PO, Hegarty BD,
Snowden MA and Carling D: Investigating the mechanism for AMP
activation of the AMP-activated protein kinase cascade. Biochem J.
403:139–148. 2007.
|
|
11
|
Zhu B, Zheng Y, Pham AD, et al:
Monoubiquitination of human histone H2B: the factors involved and
their roles in HOX gene regulation. Mol Cell. 20:601–611. 2005.
|
|
12
|
Fujiki R, Hashiba W, Sekine H, et al:
GlcNAcylation of histone H2B facilitates its monoubiquitination.
Nature. 480:557–560. 2011.
|
|
13
|
Decensi A, Puntoni M, Goodwin P, et al:
Metformin and cancer risk in diabetic patients: a systematic review
and meta-analysis. Cancer Prev Res (Phila). 3:1451–1461. 2010.
|
|
14
|
Noto H, Goto A, Tsujimoto T and Noda M:
Cancer risk in diabetic patients treated with metformin: a
systematic review and meta-analysis. PLoS One. 7:e334112012.
|
|
15
|
Lee MS, Hsu CC, Wahlqvist ML, Tsai HN,
Chang YH and Huang YC: Type 2 diabetes increases and metformin
reduces total, colorectal, liver and pancreatic cancer incidences
in Taiwanese: a representative population prospective cohort study
of 800,000 individuals. BMC Cancer. 11:202011.
|
|
16
|
Belfiore A and Frasca F: IGF and insulin
receptor signaling in breast cancer. J Mammary Gland Biol
Neoplasia. 13:381–406. 2008.
|
|
17
|
Slomiany MG, Black LA, Kibbey MM, Tingler
MA, Day TA and Rosenzweig SA: Insulin-like growth factor-1 receptor
and ligand targeting in head and neck squamous cell carcinoma.
Cancer Lett. 248:269–279. 2007.
|
|
18
|
Weiss JM, Huang WY, Rinaldi S, et al:
IGF-1 and IGFBP-3: Risk of prostate cancer among men in the
Prostate, Lung, Colorectal and Ovarian Cancer Screening Trial. Int
J Cancer. 121:2267–2273. 2007.
|
|
19
|
Dowling RJ, Zakikhani M, Fantus IG, Pollak
M and Sonenberg N: Metformin inhibits mammalian target of
rapamycin-dependent translation initiation in breast cancer cells.
Cancer Res. 67:10804–10812. 2007.
|
|
20
|
Zakikhani M, Dowling R, Fantus IG,
Sonenberg N and Pollak M: Metformin is an AMP kinase-dependent
growth inhibitor for breast cancer cells. Cancer Res.
66:10269–10273. 2006.
|
|
21
|
Shaw RJ, Bardeesy N, Manning BD, et al:
The LKB1 tumor suppressor negatively regulates mTOR signaling.
Cancer Cell. 6:91–99. 2004.
|
